The PE ratio for Neurogene stock stands at 0.48 as of Mar 20, 2025. This is calculated based on the TTM EPS of $31.92 and the stock price of $15.23 per share.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | 0.7 | N/A | $19.38 | $27.76 |
2022 | N/A | N/A | $10.18 | -$139.88 |
2021 | N/A | N/A | $96.4 | -$22 |
2020 | N/A | N/A | $282 | -$12.8 |
2019 | N/A | N/A | $246.4 | -$51.4 |
2018 | N/A | N/A | $43.2 | -$26.8 |
2017 | N/A | N/A | $235.2 | -$42.8 |
2016 | N/A | N/A | $330.2 | -$39.2 |
2015 | N/A | N/A | $249.6 | -$34.6 |
2014 | N/A | N/A | $150 | -$55 |
2013 | N/A | N/A | N/A | -$990.4 |
2012 | N/A | N/A | N/A | -$804.6 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | 1.31 | -98.42% | $41.96 | $31.92 |
Jun 2024 | 82.7 | N/A | $36.39 | $0.44 |
Mar 2024 | N/A | N/A | $50.9 | -$25.15 |
Dec 2023 | 0.7 | N/A | $19.38 | $27.76 |
Sep 2023 | N/A | N/A | $15.8 | -$211.55 |
Jun 2023 | N/A | N/A | $16.6 | -$183.6 |
Mar 2023 | N/A | N/A | $14 | -$162.52 |
Dec 2022 | N/A | N/A | $10.18 | -$139.88 |
Sep 2022 | N/A | N/A | $12.8 | -$21.32 |
Jun 2022 | N/A | N/A | $20.6 | -$22.2 |
Mar 2022 | N/A | N/A | $37.6 | -$22 |
Dec 2021 | N/A | N/A | $96.4 | -$22 |
Sep 2021 | N/A | N/A | $144.6 | -$21 |
Jun 2021 | N/A | N/A | $184.6 | -$16.2 |
Mar 2021 | N/A | N/A | $246.2 | -$14.8 |
In comparison to its peer stock ORMP, NGNE's PE ratio is lower.
Stock name | PE ratio | Market cap |
---|---|---|
NGNE Neurogene Inc | 0.44 | $209.75M |
ORMP Oramed Pharmaceuticals Inc | 21.45 | $95.14M |
OLMA Olema Pharmaceuticals Inc | N/A | $282.22M |
OMER Omeros Corp | N/A | $533.14M |
ONVO Organovo Holdings Inc | N/A | $54.98M |
ORIC Oric Pharmaceuticals Inc | N/A | $501.45M |
NGNE's price to earnings ratio is 0.48 as of Mar 20, 2025.
NGNE's PE ratio is low because its earnings per share (EPS) is high relative to its stock price.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Mar 20, 2025), Neurogene's share price is $15.23. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $31.92. Therefore, Neurogene's PE ratio for today is 0.48. PE RATIO(0.48) = STOCK PRICE($15.23) / TTM EPS($31.92)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.